Drug notes:
BAER101 Clin0 epilepsy
About:
Avenue Therapeutics is seeking to develop and commercialize therapies to treat central nervous system (CNS) disorders. There is a large unmet patient and market need in the CNS therapeutic space. Key to Avenue’s clinical development strategy is delivering near-term milestones that can build near-term value. Avenue’s portfolio includes two clinical stage programs, IV Tramadol for acute postoperative surgical pain and BAER-101 for epilepsy and acute anxiety. In particular, BAER-101 was licensed from AstraZeneca and can target the large market of patients with drug-resistant epilepsy. Through additional acquisitions in the CNS disease spaces, Avenue aims to further expand their pipeline.